Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
The approval covers the 40 mg and 80 mg tablets as bioequivalent to Astellas' reference listed drug (RLD), Xtandi, for the approved indication. While Xtandi is currently marketed in 40 mg and 80 mg strengths, Lupin's tentatively approved 120 mg and 160 mg tablets are expected to provide healthcare providers and patients with additional dosing flexibility.
Enzalutamide is indicated for the treatment of certain types of prostate cancer.
Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapeutic segments. The company's consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25.
The counter fell 1.08% to settle at Rs 2,342.15 on Thursday, 25th June 2026. The NSE and BSE remain closed today on account of Muharram.
Powered by Capital Market - Live News